Skip to content
Companies

Aminex Therapeutics

Polyamine-depleting oral therapy for solid tumors

Raised to date

$15.1M

of $30M offered across 1 Form D filing

Still open
$14.9M
Investors
162
Last filed
Dec 5, 2025

About

Aminex Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel immuno-oncology therapies. Their primary strategy is to overcome immune system suppression within the tumor microenvironment by targeting and depleting polyamines, thereby enabling the body's own immune system to attack cancer cells.

The company is a pioneer in developing a therapeutic approach based on polyamine depletion, which addresses two key immune suppressors—polyamines and myeloid-derived suppressor cells (MDSCs)—with a single combination therapy.

Funding

  • EquityFiled Dec 5, 2025Form D
    $15.1M/ $30M

Product

AMXT 1501 + DFMO Combination Therapy

Cancer Immunotherapy

The flagship product is an oral, small molecule therapy that combines AMXT 1501, a proprietary polyamine uptake inhibitor, with DFMO (eflornithine), a polyamine synthesis inhibitor. This dual-agent approach works synergistically to significantly lower polyamine levels in cancer cells and the surrounding tumor microenvironment, which in turn suppresses myeloid-derived suppressor cells (MDSCs) and restores the innate immune system's ability to fight solid tumors.

  • Oral, small molecule therapy
  • Dual-agent combination of AMXT 1501 and DFMO
  • Inhibits both polyamine uptake and synthesis

Built for

The primary end-users are cancer patients with solid tumors. The direct customers are oncology healthcare providers and hospitals, as well as pharmaceutical companies for potential licensing or partnership deals.

People on file